E. Ş. Taşçı Et Al. , "Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study," Expert Opinion on Pharmacotherapy , vol.25, no.4, pp.477-484, 2024
Taşçı, E. Ş. Et Al. 2024. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. Expert Opinion on Pharmacotherapy , vol.25, no.4 , 477-484.
Taşçı, E. Ş., KUTLU, Y., ÖLMEZ, Ö. F., Mutlu, A. U., Gündoğdu, Y., Seyyar, M., ... Şahin, E.(2024). Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. Expert Opinion on Pharmacotherapy , vol.25, no.4, 477-484.
Taşçı, Elif Et Al. "Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study," Expert Opinion on Pharmacotherapy , vol.25, no.4, 477-484, 2024
Taşçı, Elif Ş. Et Al. "Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study." Expert Opinion on Pharmacotherapy , vol.25, no.4, pp.477-484, 2024
Taşçı, E. Ş. Et Al. (2024) . "Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study." Expert Opinion on Pharmacotherapy , vol.25, no.4, pp.477-484.
@article{article, author={Elif Şenocak Taşçı Et Al. }, title={Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study}, journal={Expert Opinion on Pharmacotherapy}, year=2024, pages={477-484} }